oalib

Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99

Submit

Any time

2019 ( 39 )

2018 ( 269 )

2017 ( 273 )

2016 ( 271 )

Custom range...

Search Results: 1 - 10 of 21750 matches for " Szu-Min Hsieh "
All listed articles are free for downloading (OA Articles)
Page 1 /21750
Display every page Item
Polymorphisms of the SIPA1 gene and sporadic breast cancer susceptibility
Szu-Min Hsieh, Robert A Smith, Nicholas A Lintell, Kent W Hunter, Lyn R Griffiths
BMC Cancer , 2009, DOI: 10.1186/1471-2407-9-331
Abstract: The SNPs genotyped in this study were identified in a previous study and the genotyping assays were carried out using TaqMan SNP Genotyping Assays. The data were analysed with chi-square method and the Monte Carlo style CLUMP analysis program.Results indicated significance with SIPA1 SNP rs3741378; the CC genotype was more frequently observed in the breast cancer group compared to the disease-free control group, indicating the variant C allele was associated with increased breast cancer incidence.This observation indicates SNP rs3741378 as a novel potential sporadic breast cancer predisposition SNP. While it showed association with hormonal receptor status in breast cancer group in a previous pilot study, this exonic missense SNP (Ser (S) to Phe (F)) changes a hydrophilic residue (S) to a hydrophobic residue (F) and may significantly alter the protein functions of SIPA1 in breast tumourgenesis. SIPA1 SNPs rs931127 (5' near gene), and rs746429 (synonymous (Ala (A) to Ala (A)), did not show significant associations with breast cancer incidence, yet were associated with lymph node metastasis in the previous study. This suggests that SIPA1 may be involved in different stages of breast carcinogenesis and since this study replicates a previous study of the associated SNP, it implicates variants of the SIPA1 gene as playing a potential role in breast cancer.The novel breast cancer gene SIPA1 was originally identified as a candidate gene for breast cancer metastasis from mouse studies. Mouse Sipa1 was established as a candidate for underlying the breast cancer metastasis efficiency modifier locus Mtes 1 by Park et al [1]. The Mtes 1 loci in the mouse genome were recognized as a genetic region that substantially influenced the metastatic efficiency of mammary tumours in the mouse. The mouse Mtes 1 locus is orthologous to human chromosome 11q12-11q13, which is known to harbor the metastasis suppressor gene BRMS1. Utilizing a Multiple Cross Mapping strategy, mouse Sipa1 was id
Distinct inherited metastasis susceptibility exists for different breast cancer subtypes: a prognosis study
Szu-Min Hsieh, Maxime P Look, Anieta M Sieuwerts, John A Foekens, Kent W Hunter
Breast Cancer Research , 2009, DOI: 10.1186/bcr2412
Abstract: The study population consisted of 1863 Dutch patients with operable primary breast cancer from Rotterdam, The Netherlands. Genomic DNA was genotyped for the missense Pro436Leu RRP1B single nucleotide polymorphism (SNP) rs9306160 and the intronic SIPA1 SNP rs2448490 by SNP-specific PCR.A significant association of variants in RRP1B with metastasis-free survival was observed (P = 0.012), validating the role of RRP1B with inherited metastatic susceptibility. Stratification of patients revealed that association with patients' survival was found to be specifically restricted to estrogen receptor positive, lymph node-negative (ER+/LN-) patients (P = 0.011). The specific association with metastasis-free survival only in ER+/LN- patients was replicated for SIPA1, a second metastasis susceptibility gene known to physically interact with RRP1B (P = 0.006). Combining the genotypes of these two genes resulted in the significant ability to discriminate patients with poor metastasis-free survival (HR: 0.40, 95% CI: 0.24 to 0.68, P = 0.001).These results validate SIPA1 and RRP1B as metastasis susceptibility genes and suggest that genotyping assays may be a useful supplement to other clinical and molecular indicators of prognosis. The results also suggest that lymphatic and hematogeneous metastases are genetically distinct that may involve different mechanisms. If true, these results suggest that metastatic disease, like primary breast cancer, may be multiple diseases and that stratification of late stage patients may therefore be required to fully understand breast cancer progression and metastasis.Cancer mortality can be attributed mostly to metastatic disease, with an estimated 90% of deaths associated with solid tumors resulting from the pathophysiological impact of secondary disease. Despite many advances in both basic science and applied clinical research over recent years, advanced disseminated disease remains an incurable condition. Further investigations into the myriad of
Association between amebic liver abscess and Human Immunodeficiency Virus infection in Taiwanese subjects
Meng-Shuian Hsu, Szu-Min Hsieh, Mao-Yuan Chen, Chien-Ching Hung, Shan-Chwen Chang
BMC Infectious Diseases , 2008, DOI: 10.1186/1471-2334-8-48
Abstract: Among ALA patients, the proportion of HIV-positive individuals increased during the study period. ALA was the first major clinical presentation in 54% of HIV patients with ALA. Overall, 58% (14/24) of HIV-infected patients had a CD4+ count > 200 cells/μL and 82.1% (23/28) had no concurrent opportunistic infection or other evidence of HIV infection. There was no marked difference in clinical characteristics between HIV-positive and HIV-negative ALA patients except the level of leukocytosis.While the clinical characteristics described herein cannot be used to determine whether ALA patients have HIV infection, routine HIV testing is recommended in patients with ALA, even in the absence of HIV symptoms.Amebiasis, a parasitic infection caused by Entamoeba histolytica, is transmitted by ingestion of food or water containing the cyst form of the parasite, and results in amebic colitis and the formation of amebic liver abscess (ALA). Amebiasis is one of the most infectious diseases in the world with developing countries, including Central and South America, tropical Asia, and Africa, as areas of highest incidence. In developed countries, individuals at increased risk for amebiasis include immigrants from developing countries, travelers to the tropics, residents of institutions for mentally retarded individuals, homosexual men, and immunodepressed individuals. Patients with advanced human immunodeficiency virus (HIV) represent one of the highest risk groups of invasive amebiasis [1,2]. Luminal agents such as paromomycin, diloxanide furoate, and iodoquinol are typically used for the treatment of amebiasis caused by E. histolytica infection [1].ALA is the most common extraintestinal manifestation of E. histolytica infection. E. histolytica transmission is associated with the oral-fecal pathway and is facilitated by poor sanitary conditions [3]. Traveling to endemic areas, with the possibility of ingesting contaminated food or water, remains a risk for contracting ALA. In Taiwa
Impact of first-line protease inhibitors on predicted resistance to tipranavir in HIV-1-infected patients with virological failure
Szu-Min Hsieh, Sui-Yuan Chang, Chien-Ching Hung, Wang-Huei Sheng, Mao-Yuan Chen, Shan-Chwen Chang
BMC Infectious Diseases , 2009, DOI: 10.1186/1471-2334-9-154
Abstract: To assess the resistance levels to TPV of HIV-1 from patients with treatment failure to first-line PIs, patients who experienced virological failure were tested for genotypic resistance of HIV-1 since August 2006 in National Taiwan University Hospital. Patients were enrolled for this analysis if their failed regimens contained > 12 weeks of atazanavir or lopinavir/ritonavir (defined as ATV group and LPV/r group, respectively), but were excluded if they experienced both or other PIs. The levels of genotypic resistance to TPV/r were determined by TPV mutation score.Till May 2008, 21 subjects in ATV group and 20 subjects in LPV/r group were enrolled. The TPV mutation scores in subjects in LPV/r group were significantly higher than these in ATV group (median, 3 vs 1, P = 0.007). 95.2% subjects in ATV group and only 45% subjects in LPV/r group had an estimated maximal virological response to TPV/r (P < 0.001). The resistance levels to TPV/r correlated with the duration of exposure to first-line PIs, whether in ATV or LPV/r group.Cross-resistance from first-line PIs may impede the effectiveness of TPV/r-containing salvage therapy. TPV/r should be used cautiously for patients with virological failure to LPV/r especially long duration of exposure.Tipranavir (TPV) is a recently approved nonpeptidic protease inhibitor (PI) of HIV-1 and ritonavir (RTV)-boosted tipranavir (TPV/r) has been indicated for treatment-experienced patients or those infected with PIs-resistant HIV-1 [1-3] thus TPV/r is only approved in highly treated patients with a documented resistance to multiple PIs in Taiwan.However, TPV shares some resistance-associated mutations (such as M36I, M46L, I54V, I84V, etc) with other PIs [4]. Thus, in clinical practice, whether the HIV-1 derived from the patients with virological failure to the regimens containing first-line PIs remains susceptible to TPV/r may be questionable. RTV-boosted lopinavir (LPV/r) and atazanavir (ATV) are recommended as the preferred first-li
Admissions to intensive care unit of HIV-infected patients in the era of highly active antiretroviral therapy: etiology and prognostic factors
Hou-Hsien Chiang, Chien-Ching Hung, Chang-Min Lee, Hsuan-Yu Chen, Mao-Yuan Chen, Wang-Huei Sheng, Szu-Min Hsieh, Hsin-Yun Sun, Chao-Chi Ho, Chong-Jen Yu
Critical Care , 2011, DOI: 10.1186/cc10419
Abstract: Medical records of all HIV-infected adults who were admitted to ICU at a university hospital in Taiwan from 2001 to 2010 were reviewed to record information on patient demographics, receipt of HAART, and reason for ICU admission. Factors associated with hospital mortality were analyzed.During the 10-year study period, there were 145 ICU admissions for 135 patients, with respiratory failure being the most common cause (44.4%), followed by sepsis (33.3%) and neurological disease (11.9%). Receipt of HAART was not associated with survival. However, CD4 count was independently predictive of hospital mortality (adjusted odds ratio [AOR], per-10 cells/mm3 decrease, 1.036; 95% confidence interval [CI], 1.003 to 1.069). Admission diagnosis of sepsis was independently associated with hospital mortality (AOR, 2.91; 95% CI, 1.11 to 7.62). A hospital-to-ICU interval of more than 24 hours and serum albumin level (per 1-g/dl decrease) were associated with increased hospital mortality, but did not reach statistical significance in multivariable analysis.Respiratory failure was the leading cause of ICU admissions among HIV-infected patients in Taiwan. Outcome during the ICU stay was associated with CD4 count and the diagnosis of sepsis, but was not associated with HAART in this study.After the introduction of highly active antiretroviral therapy (HAART), the life expectancy of HIV-infected patients has significantly increased and the incidence of illnesses associated with AIDS markedly decreased [1]. Nevertheless, HIV-related complications that may require critical care support continue to occur in HIV-infected patients who are unaware of their HIV serostatus and do not initiate HAART and appropriate antimicrobial prophylaxis, or who fail to respond to HAART with virological and immunologic failures. These patients may also require critical care because of other co-morbidities such as hepatitis co-infections, alcoholism, or chronic obstructive pulmonary disease [2]. Although respira
Risk of pneumocystosis after early discontinuation of prophylaxis among HIV-infected patients receiving highly active antiretroviral therapy
Chien-Yu Cheng, Mao-Yuan Chen, Szu-Min Hsieh, Wang-Huei Sheng, Hsin-Yun Sun, Yi-Chun Lo, Wen-Chun Liu, Chien-Ching Hung
BMC Infectious Diseases , 2010, DOI: 10.1186/1471-2334-10-126
Abstract: Medical records of 660 HIV-infected patients with baseline CD4 counts <200 cells/μL who sought HIV care and received HAART at a university hospital in Taiwan between 1 April, 1997 and 30 September, 2007 were reviewed to assess the incidence rate of pneumocystosis after discontinuation of prophylaxis for pneumocystosis.The incidence rate of pneumocystosis after HAART was 2.81 per 100 person-years among 521 patients who did not initiate prophylaxis or had early discontinuation of prophylaxis, which was significantly higher than the incidence rate of 0.45 per 100 person-years among 139 patients who continued prophylaxis until CD4 counts increased to ≧200 cells/μL (adjusted risk ratio, 5.32; 95% confidence interval, 1.18, 23.94). Among the 215 patients who had early discontinuation of prophylaxis after achievement of undetectable plasma HIV RNA load, the incidence rate of pneumocystosis was reduced to 0.31 per 100 person-years, which was similar to that of the patients who continued prophylaxis until CD4 counts increased to ≧200 cells/μL (adjusted risk ratio, 0.63; 95% confidence interval, 0.03, 14.89).Compared with the risk of pneumocystosis among patients who continued prophylaxis until CD4 counts increased to ≧200 cells/μL after HAART, the risk was significantly higher among patients who discontinued prophylaxis when CD4 counts remained <200 cells/μL, while the risk could be reduced among patients who achieved undetectable plasma HIV RNA load after HAART.With the widespread use of highly active antiretroviral therapy (HAART) after 1996, HIV-related mortality and the risks of several major opportunistic infections, such as Pneumocystis jirovecii pneumonia (formerly P. carinii pneumonia), disseminated Mycobacterium avium complex infection, and cytomegalovirus diseases, have significantly declined in patients receiving HAART [1-3]. For example, an incidence rate of 20 cases of pneumocystosis per 100 person-months was reported in the pre-HAART era [4], which decreased to
Formalin-Inactivated EV71 Vaccine Candidate Induced Cross-Neutralizing Antibody against Subgenotypes B1, B4, B5 and C4A in Adult Volunteers
Ai-Hsiang Chou, Chia-Chyi Liu, Jui-Yuan Chang, Renee Jiang, Yi-Chin Hsieh, Amanda Tsao, Chien-Long Wu, Ju-Lan Huang, Chang-Phone Fung, Szu-Min Hsieh, Ya-Fang Wang, Jen-Ren Wang, Mei-Hua Hu, Jen-Ron Chiang, Ih-Jen Su, Pele Choi-Sing Chong
PLOS ONE , 2013, DOI: 10.1371/journal.pone.0079783
Abstract: Background Enterovirus 71 (EV71) has caused several epidemics of hand, foot and mouth diseases (HFMD) in Asia. No effective EV71 vaccine is available. A randomized and open-label phase I clinical study registered with ClinicalTrials.gov #NCT01268787, aims to evaluate the safety, reactogenicity and immunogenicity of a formalin-inactivated EV71 vaccine candidate (EV71vac) at 5- and 10-μg doses. In this study we report the cross-neutralizing antibody responses from each volunteer against different subgenotypes of EV71 and CVA16. Methods Sixty eligible healthy adults were recruited and vaccinated. Blood samples were obtained on day 0, 21 and 42 and tested against B1, B4, B5, C2, C4A, C4B and CVA16 for cross-neutralizing antibody responses. Results The immunogenicity of both 5- and 10- μg doses were found to be very similar. Approximately 45% of the participants had <8 pre-vaccination neutralization titers (Nt) against the B4 vaccine strain. After the first EV71vac immunization, 95% of vaccinees have >4-fold increase in Nt, but there was no further increase in Nt after the second dose. EV71vac induced very strong cross-neutralizing antibody responses in >85% of volunteers without pre-existing Nt against subgenotype B1, B5 and C4A. EV71vac elicited weak cross-neutralizing antibody responses (~20% of participants) against a C4B and Coxsackie virus A16. Over 90% of vaccinated volunteers did not develop cross-neutralizing antibody responses (Nt<8) against a C2 strain. EV71vac can boost and significantly enhance the neutralizing antibody responses in volunteers who already had pre-vaccination antibodies against EV71 and/or CVA16. Conclusion EV71vac is efficient in eliciting cross-neutralizing antibody responses against EV71 subgenotypes B1, B4, B5, and C4A, and provides the rationale for its evaluation in phase II clinical trials. Trial Registration ClinicalTrials.gov __NCT01268787
Effect of Growth Hormone on Dawn Phenomenon in Healthy Adults  [PDF]
Kuang-Chung Shih, Sheng-Hwu Hsieh, Chii-Min Hwu, Ching-Fai Kwok, Szu-Han Chiu, Yu-Ching Chou, Low-Tone Ho
Open Journal of Endocrine and Metabolic Diseases (OJEMD) , 2015, DOI: 10.4236/ojemd.2015.56008
Abstract: The purpose of this study was to investigate the involvement of growth hormone in the diurnal variation of insulin sensitivity in healthy adults. Afternoon (16:00 hr) or night (23:00 hr) pretreatment with a subcutaneous injection of normal saline, human growth hormone to mimic the normal nocturnal rise in growth hormone, or octreotide to inhibit endogenous growth hormone secretion to create a state of relative nocturnal growth hormone deficiency, was given 16 hours before undergoing the modified insulin suppression test in healthy subjects. The morning and evening experiments were separated by an interval of at least 3 days. Thus, each subject was tested on six separate occasions arranged in a random order. A higher value of the steady-state plasma glucose (SSPG) is indicative of lower insulin sensitivity. Plasma glucose, serum insulin, insulin-like growth factor-1, nonesterified fatty acids (NEFA), and metabolic clearance rate of insulin (MCRI) were measured. In the normal saline and human growth hormone groups, SSPG levels were lower in the morning than in the evening. Evening SSPG levels, MCRI, and NEFA concentrations were higher in the participants treated with normal saline and growth hormone than in the octreotide group. Differences in SSPG levels between the morning and evening values were higher in the participants pretreated with normal saline and growth hormone than in those treated with octreotide. A diurnal variation in insulin sensitivity existed in healthy subjects. These results provided direct evidence that the role of growth hormone in regulating insulin sensitivity might be related to changes in the MCRI and the metabolism of NEFA in healthy subjects.
Phase diagram of microcavity polariton condensates with a harmonic potential trap
Ting-Wei Chen,Min g-Dar Wei,Szu-Cheng Cheng,Wen-Feng Hsieh
Physics , 2013, DOI: 10.1016/j.ssc.2013.09.035
Abstract: We theoretically explore the phase transition in inhomogeneous exciton-polariton condensates with variable pumping conditions. Through Bogoliubov excitations to the radial-symmetric solutions of complex Gross-Pitaevskii equation, we determine not only the bifurcation of stable and unstable modes by the sign of fluid compressibility but also two distinct stable modes which are characterized by the elementary excitations and the stability of singly quantized vortex. One state is the quasi-condensate BKT phase with Goldstone flat dispersion; the other state is the localized-BEC phase which exhibits linear-type dispersion and has an excitation energy gap at zero momentum.
Delayed Airway Obstruction in Posterior Fossa Craniotomy with Park-Bench Position—A Case Report and Review of the Literatures  [PDF]
Szu-Kai Hsu, Cheng-Ta Hsieh, Chih-Ta Huang, Jing-Shan Huang
Surgical Science (SS) , 2012, DOI: 10.4236/ss.2012.311104
Abstract: Background: Park-bench position is a commonly used position in patients operated with cerebellopontine tumor, microvascular decompression, or lesions of cerebellar hemisphere and vertebral artery. Several complications associated with this positioning have been described. However, the delayed airway complication resulting from park-bench position has been rarely reported in the literatures. Herein, we report a rare case of delayed airway obstruction after a posterior-fossa craniotomy with park-bench position for acoustic neuroma. Case presentation: A 43-year-old woman, who has a right acoustic neuroma, was placed in the park-bench position for a posterior-fossa craniotomy. The anesthesia and operation were performed smoothly. However, progressive swelling in the left neck with extending to left face occurred two hours after endo-tracheal extubation. Computed tomographic scan of neck revealed diffuse swelling of the muscles and deep soft tissue in the left side. No obvious embolization of vascular system including jugular vein was found in the sonography. Because of obstruction in upper airway, orotracheal intubation and a head-up position were performed. The clinical symptoms improved gradually since the third post-operative day. She was discharged with obvious complications on the 23rd day after the operation. Conclusion: The possible mechanisms may originate from the kinking of the jugular vein due to hyper-flexed neck position during surgery. To prevent such complication, we must take great care of the anesthetized patients when placed in the forced neck position and always keep this rare but so critical complication in mind.
Page 1 /21750
Display every page Item


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.